Atemur Diskus may be available in the countries listed below.
Fluticasone propionate (a derivative of Fluticasone) is reported as an ingredient of Atemur Diskus in the following countries:
International Drug Name Search
Naproxi may be available in the countries listed below.
Naproxen is reported as an ingredient of Naproxi in the following countries:
International Drug Name Search
Parameba may be available in the countries listed below.
Paromomycin is reported as an ingredient of Parameba in the following countries:
International Drug Name Search
Mikelan LA may be available in the countries listed below.
Carteolol hydrochloride (a derivative of Carteolol) is reported as an ingredient of Mikelan LA in the following countries:
International Drug Name Search
Cefuroxima Sala may be available in the countries listed below.
Cefuroxime sodium salt (a derivative of Cefuroxime) is reported as an ingredient of Cefuroxima Sala in the following countries:
International Drug Name Search
Generic Name: diphtheria, hepatitis B, pertussis (acellular), polio, and tetanus vaccine (dif THEER ee a, hep a TYE tis B, per TUS iss, POE lee oh, and TET a nus)
Brand Names: Pediarix
Diphtheria, pertussis, and tetanus are serious diseases caused by bacteria.
Diphtheria causes a thick coating in the nose, throat, and airways. It can lead to breathing problems, paralysis, heart failure, or death.
Pertussis (whooping cough) causes coughing so severe that it interferes with eating, drinking, or breathing. These spells can last for weeks and can lead to pneumonia, seizures (convulsions), brain damage, and death.
Tetanus (lockjaw) causes painful tightening of the muscles, usually all over the body. It can lead to "locking" of the jaw so the victim cannot open the mouth or swallow. Tetanus leads to death in about 1 out of 10 cases.
Hepatitis B and polio are serious diseases caused by virus.
Hepatitis B is a disease of the liver that is spread through blood or bodily fluids, sexual contact or sharing IV drug needles with an infected person, or during childbirth when the mother is infected. Hepatitis causes inflammation of the liver, vomiting, and jaundice (yellowing of the skin or eyes). Hepatitis can lead to liver cancer, cirrhosis, or death.
Polio affects the central nervous system and spinal cord. It can cause muscle weakness and paralysis. Polio is a life-threatening condition because it can paralyze the muscles that help you breathe.
Diphtheria, hepatitis B, pertussis, and polio are spread from person to person. Tetanus enters the body through a cut or wound.
The diphtheria, hepatitis B, pertussis acellular, polio, and tetanus vaccine is used to help prevent these diseases in children who are ages 6 weeks to 6 years old, before the child has reached his or her 7th birthday.
This vaccine works by exposing your child to a small dose of the bacteria or a protein from the bacteria, which causes the body to develop immunity to the disease. This vaccine will not treat an active infection that has already developed in the body.
Like any vaccine, the diphtheria, hepatitis B, pertussis acellular, polio, and tetanus vaccine may not provide protection from disease in every person.
The diphtheria, hepatitis B, pertussis, polio, and tetanus vaccine is given in a series of shots. The first shot is usually given when the child is 2 months old. The booster shots are then given at 4 months and 6 months of age. Your child's individual booster schedule may be different from these guidelines. Follow your doctor's instructions or the schedule recommended by the health department of the state you live in.
Be sure your child receives all recommended doses of this vaccine. If your child does not receive the full series of vaccines, he or she may not be fully protected against the disease.
Your child can still receive a vaccine if he or she has a cold or fever. In the case of a more severe illness with a fever or any type of infection, wait until the child gets better before receiving this vaccine.
Keep track of any and all side effects your child has after receiving this vaccine. When the child receives a booster dose, you will need to tell the doctor if the previous shots caused any side effects.
Becoming infected with diphtheria, hepatitis B, pertussis, polio, or tetanus is much more dangerous to your child's health than receiving the vaccine to protect against these diseases. Like any medicine, this vaccine can cause side effects, but the risk of serious side effects is extremely low.
A hepatitis B vaccine will not protect your child against infection with hepatitis A, C, and E, or other viruses that affect the liver. It may also not protect the child from hepatitis B if he or she is already infected with the virus, even if the child does not yet show symptoms.
Your child should also not receive this vaccine if he or she has:
severe or uncontrolled epilepsy or other seizure disorder;
if the child has received cancer chemotherapy or radiation treatment in the past 3 months.
Your child may not be able to receive this vaccine if he or she has ever received a similar vaccine that caused any of the following:
a very high fever (over 104 degrees);
a neurologic disorder or disease affecting the brain;
excessive crying for 3 hours or longer;
fainting or going into shock;
Guillain-Barré syndrome (within 6 weeks after receiving a diphtheria, tetanus, or pertussis vaccine);
seizure (convulsions); or
a severe skin reaction.
Before receiving this vaccine, tell the doctor if your child has:
a bleeding or blood clotting disorder such as hemophilia or easy bruising;
a history of seizures;
an allergy to latex rubber;
a weak immune system caused by disease or by taking certain medicines or receiving cancer treatments;
if the child is taking a blood thinner such as warfarin (Coumadin); or
if it has been less than 6 weeks since the child last received a vaccine.
Your child can still receive a vaccine if he or she has a cold or fever. In the case of a more severe illness with a fever or any type of infection, wait until the child gets better before receiving this vaccine.
This vaccine is given as an injection (shot) into a muscle. Your child will receive this injection in a doctor's office or other clinic setting.
The diphtheria, hepatitis B, pertussis, polio, and tetanus vaccine is given in a series of shots. The first shot is usually given when the child is 2 months old. The booster shots are then given at 4 months and 6 months of age. Your child's individual booster schedule may be different from these guidelines. Follow your doctor's instructions or the schedule recommended by the health department of the state you live in.
Your doctor may recommend treating fever and pain with an aspirin-free pain reliever such as acetaminophen (Tylenol) or ibuprofen (Motrin, Advil, and others) when the shot is given and for the next 24 hours. Follow the label directions or your doctor's instructions about how much of this medicine to give your child.
Contact your doctor if you will miss a booster dose or if you get behind schedule. The next dose should be given as soon as possible. There is no need to start over.
Be sure your child receives all recommended doses of this vaccine. If your child does not receive the full series of vaccines, he or she may not be fully protected against the disease.
An overdose of this vaccine is unlikely to occur.
There are no restrictions on food, beverages, or activity before or after receiving this vaccine unless your child's doctor has told you otherwise.
Becoming infected with diphtheria, hepatitis B, pertussis, polio, or tetanus is much more dangerous to your child's health than receiving the vaccine to protect against these diseases. Like any medicine, this vaccine can cause side effects, but the risk of serious side effects is extremely low.
Call your doctor at once if the child has any of these serious side effects:
extreme drowsiness, fainting;
fussiness, irritability, crying for an hour or longer;
seizure (black-out or convulsions); or
high fever (can occur for up to 4 days after the vaccine).
Less serious side effects include:
redness, pain, tenderness, or swelling where the shot was given;
mild fever;
mild fussiness or crying;
joint pain, body aches;
loss of appetite; or
nausea, vomiting, diarrhea.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report vaccine side effects to the US Department of Health and Human Services at 1-800-822-7967.
Usual Pediatric Dose for Poliomyelitis Prophylaxis:
Active immunization against diphtheria, tetanus, pertussis (whooping cough), all known subtypes of hepatitis B virus, and poliomyelitis caused by poliovirus Types 1, 2, and 3:
6 months to 5 years:
3 doses of 0.5 mL, given intramuscularly, at 6- to 8-week intervals (preferably 8 weeks). The customary age for the first dose is 2 months of age, but it may be given starting at 6 weeks of age. The preferred administration site is the anterolateral aspect of the thigh for children younger than 1 year. In older children, the deltoid muscle is usually large enough for an intramuscular injection. The vaccine should not be injected in the gluteal area or areas where there may be a major nerve trunk. Gluteal injections may result in suboptimal hepatitis B immune response.
Modified Schedules:
Children Previously Vaccinated With One or More Doses of Hepatitis B Vaccine: Infants born of HBsAg-negative mothers and who received a dose of hepatitis B vaccine at or shortly after birth may be administered 3 doses of diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX) according to the recommended schedule.
Children Previously Vaccinated With One or More Doses of INFANRIX (diphtheria/tetanus/pertussis,acel): diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX) may be used to complete the first 3 doses of the DTaP series in infants who have received 1 or 2 doses of INFANRIX and are also scheduled to receive the other vaccine components of diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX).
Children Previously Vaccinated With One or More Doses of Poliovirus vaccine, inactivated (IPV):
diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX) may be used to complete the first 3 doses of the IPV series in infants who have received 1 or 2 doses of IPV and are also scheduled to receive the other vaccine components of diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX).
Usual Pediatric Dose for Diphtheria Prophylaxis:
Active immunization against diphtheria, tetanus, pertussis (whooping cough), all known subtypes of hepatitis B virus, and poliomyelitis caused by poliovirus Types 1, 2, and 3:
6 months to 5 years:
3 doses of 0.5 mL, given intramuscularly, at 6- to 8-week intervals (preferably 8 weeks). The customary age for the first dose is 2 months of age, but it may be given starting at 6 weeks of age. The preferred administration site is the anterolateral aspect of the thigh for children younger than 1 year. In older children, the deltoid muscle is usually large enough for an intramuscular injection. The vaccine should not be injected in the gluteal area or areas where there may be a major nerve trunk. Gluteal injections may result in suboptimal hepatitis B immune response.
Modified Schedules:
Children Previously Vaccinated With One or More Doses of Hepatitis B Vaccine: Infants born of HBsAg-negative mothers and who received a dose of hepatitis B vaccine at or shortly after birth may be administered 3 doses of diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX) according to the recommended schedule.
Children Previously Vaccinated With One or More Doses of INFANRIX (diphtheria/tetanus/pertussis,acel): diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX) may be used to complete the first 3 doses of the DTaP series in infants who have received 1 or 2 doses of INFANRIX and are also scheduled to receive the other vaccine components of diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX).
Children Previously Vaccinated With One or More Doses of Poliovirus vaccine, inactivated (IPV):
diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX) may be used to complete the first 3 doses of the IPV series in infants who have received 1 or 2 doses of IPV and are also scheduled to receive the other vaccine components of diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX).
Usual Pediatric Dose for Pertussis Prophylaxis:
Active immunization against diphtheria, tetanus, pertussis (whooping cough), all known subtypes of hepatitis B virus, and poliomyelitis caused by poliovirus Types 1, 2, and 3:
6 months to 5 years:
3 doses of 0.5 mL, given intramuscularly, at 6- to 8-week intervals (preferably 8 weeks). The customary age for the first dose is 2 months of age, but it may be given starting at 6 weeks of age. The preferred administration site is the anterolateral aspect of the thigh for children younger than 1 year. In older children, the deltoid muscle is usually large enough for an intramuscular injection. The vaccine should not be injected in the gluteal area or areas where there may be a major nerve trunk. Gluteal injections may result in suboptimal hepatitis B immune response.
Modified Schedules:
Children Previously Vaccinated With One or More Doses of Hepatitis B Vaccine: Infants born of HBsAg-negative mothers and who received a dose of hepatitis B vaccine at or shortly after birth may be administered 3 doses of diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX) according to the recommended schedule.
Children Previously Vaccinated With One or More Doses of INFANRIX (diphtheria/tetanus/pertussis,acel): diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX) may be used to complete the first 3 doses of the DTaP series in infants who have received 1 or 2 doses of INFANRIX and are also scheduled to receive the other vaccine components of diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX).
Children Previously Vaccinated With One or More Doses of Poliovirus vaccine, inactivated (IPV):
diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX) may be used to complete the first 3 doses of the IPV series in infants who have received 1 or 2 doses of IPV and are also scheduled to receive the other vaccine components of diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX).
Usual Pediatric Dose for Tetanus Prophylaxis:
Active immunization against diphtheria, tetanus, pertussis (whooping cough), all known subtypes of hepatitis B virus, and poliomyelitis caused by poliovirus Types 1, 2, and 3:
6 months to 5 years:
3 doses of 0.5 mL, given intramuscularly, at 6- to 8-week intervals (preferably 8 weeks). The customary age for the first dose is 2 months of age, but it may be given starting at 6 weeks of age. The preferred administration site is the anterolateral aspect of the thigh for children younger than 1 year. In older children, the deltoid muscle is usually large enough for an intramuscular injection. The vaccine should not be injected in the gluteal area or areas where there may be a major nerve trunk. Gluteal injections may result in suboptimal hepatitis B immune response.
Modified Schedules:
Children Previously Vaccinated With One or More Doses of Hepatitis B Vaccine: Infants born of HBsAg-negative mothers and who received a dose of hepatitis B vaccine at or shortly after birth may be administered 3 doses of diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX) according to the recommended schedule.
Children Previously Vaccinated With One or More Doses of INFANRIX (diphtheria/tetanus/pertussis,acel): diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX) may be used to complete the first 3 doses of the DTaP series in infants who have received 1 or 2 doses of INFANRIX and are also scheduled to receive the other vaccine components of diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX).
Children Previously Vaccinated With One or More Doses of Poliovirus vaccine, inactivated (IPV):
diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX) may be used to complete the first 3 doses of the IPV series in infants who have received 1 or 2 doses of IPV and are also scheduled to receive the other vaccine components of diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX).
Usual Pediatric Dose for Hepatitis B Prophylaxis:
Active immunization against diphtheria, tetanus, pertussis (whooping cough), all known subtypes of hepatitis B virus, and poliomyelitis caused by poliovirus Types 1, 2, and 3:
6 months to 5 years:
3 doses of 0.5 mL, given intramuscularly, at 6- to 8-week intervals (preferably 8 weeks). The customary age for the first dose is 2 months of age, but it may be given starting at 6 weeks of age. The preferred administration site is the anterolateral aspect of the thigh for children younger than 1 year. In older children, the deltoid muscle is usually large enough for an intramuscular injection. The vaccine should not be injected in the gluteal area or areas where there may be a major nerve trunk. Gluteal injections may result in suboptimal hepatitis B immune response.
Modified Schedules:
Children Previously Vaccinated With One or More Doses of Hepatitis B Vaccine: Infants born of HBsAg-negative mothers and who received a dose of hepatitis B vaccine at or shortly after birth may be administered 3 doses of diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX) according to the recommended schedule.
Children Previously Vaccinated With One or More Doses of INFANRIX (diphtheria/tetanus/pertussis,acel): diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX) may be used to complete the first 3 doses of the DTaP series in infants who have received 1 or 2 doses of INFANRIX and are also scheduled to receive the other vaccine components of diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX).
Children Previously Vaccinated With One or More Doses of Poliovirus vaccine, inactivated (IPV):
diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX) may be used to complete the first 3 doses of the IPV series in infants who have received 1 or 2 doses of IPV and are also scheduled to receive the other vaccine components of diphtheria/hepB/pertussis,acel/polio/tetanus vaccine (PEDIARIX).
Also tell the doctor if your child has received drugs or treatments in the past 2 weeks that can weaken the immune system, including:
an oral, nasal, inhaled, or injectable steroid medicine;
medications to treat psoriasis, rheumatoid arthritis, or other autoimmune disorders, such as azathioprine (Imuran), efalizumab (Raptiva), etanercept (Enbrel), leflunomide (Arava), and others; or
medicines to treat or prevent organ transplant rejection, such as basiliximab (Simulect), cyclosporine (Sandimmune, Neoral, Gengraf), muromonab-CD3 (Orthoclone), mycophenolate mofetil (CellCept), sirolimus (Rapamune), or tacrolimus (Prograf).
If your child is using any of these drugs, he or she may not be able to receive the vaccine.
There may be other drugs that can affect this vaccine. Tell your doctor about all the prescription and over-the-counter medications your child has received. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your child's doctor.
Sedapen may be available in the countries listed below.
Diazepam is reported as an ingredient of Sedapen in the following countries:
International Drug Name Search
Omnitrop may be available in the countries listed below.
Somatropine is reported as an ingredient of Omnitrop in the following countries:
International Drug Name Search
Prostamide may be available in the countries listed below.
Flutamide is reported as an ingredient of Prostamide in the following countries:
International Drug Name Search
Losartan Acostlabs may be available in the countries listed below.
Losartan potassium salt (a derivative of Losartan) is reported as an ingredient of Losartan Acostlabs in the following countries:
International Drug Name Search
In the US, Cleocin T (clindamycin topical) is a member of the drug class topical acne agents and is used to treat Acne and Perioral Dermatitis.
US matches:
Clindamycin is reported as an ingredient of Cleocin T in the following countries:
Clindamycin dihydrogen phosphate (a derivative of Clindamycin) is reported as an ingredient of Cleocin T in the following countries:
International Drug Name Search
Axetine may be available in the countries listed below.
Cefuroxime sodium salt (a derivative of Cefuroxime) is reported as an ingredient of Axetine in the following countries:
International Drug Name Search
Vesparax may be available in the countries listed below.
Quetiapine fumarate (a derivative of Quetiapine) is reported as an ingredient of Vesparax in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Rec.INN
0000090-69-7
C22-H27-N-O2
337
Analeptic
Smoking cessation
Ethanone, 2-[6-(2-hydroxy-2-phenylethyl)-1-methyl-2-piperidinyl]-1-phenyl-, [2R-[2α,6α(S*)]]-
International Drug Name Search
Glossary
| BAN | British Approved Name |
| BANM | British Approved Name (Modified) |
| DCF | Dénomination Commune Française |
| DCIT | Denominazione Comune Italiana |
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Biofast may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Amoxicillin is reported as an ingredient of Biofast in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Tylosin phosphate (a derivative of Tylosin) is reported as an ingredient of Medic Meal T in the following countries:
International Drug Name Search
Galantase may be available in the countries listed below.
Tilactase is reported as an ingredient of Galantase in the following countries:
International Drug Name Search
Polycarbophil Calcium may be available in the countries listed below.
Polycarbophil Calcium (BANM) is known as Polycarbophil in the US.
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
Nystatin Actavis Cream may be available in the countries listed below.
Nystatin is reported as an ingredient of Nystatin Actavis Cream in the following countries:
International Drug Name Search
Fluconazole Panpharma may be available in the countries listed below.
Fluconazole is reported as an ingredient of Fluconazole Panpharma in the following countries:
International Drug Name Search
Loproc may be available in the countries listed below.
Omeprazole is reported as an ingredient of Loproc in the following countries:
International Drug Name Search
Epadel S may be available in the countries listed below.
Icosapent ethyl ester (a derivative of Icosapent) is reported as an ingredient of Epadel S in the following countries:
International Drug Name Search
Iriten may be available in the countries listed below.
Irinotecan is reported as an ingredient of Iriten in the following countries:
International Drug Name Search
Amantadin-ratiopharm may be available in the countries listed below.
Amantadine is reported as an ingredient of Amantadin-ratiopharm in the following countries:
Amantadine hydrochloride (a derivative of Amantadine) is reported as an ingredient of Amantadin-ratiopharm in the following countries:
Amantadine sulfate (a derivative of Amantadine) is reported as an ingredient of Amantadin-ratiopharm in the following countries:
International Drug Name Search
Rec.INN
0050924-49-7
C9-H13-N3-O6
259
Immunosuppressant
Antifungal agent
1H-Imidazole-4-carboxamide, 5-hydroxy-1-ĂŸ-D-ribofuranosyl-
International Drug Name Search
Glossary
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Voltaren K Migräne may be available in the countries listed below.
Diclofenac potassium salt (a derivative of Diclofenac) is reported as an ingredient of Voltaren K Migräne in the following countries:
International Drug Name Search
Methylergometrin Spofa may be available in the countries listed below.
Methylergometrine tartrate (a derivative of Methylergometrine) is reported as an ingredient of Methylergometrin Spofa in the following countries:
International Drug Name Search
Praticilin may be available in the countries listed below.
Ampicillin is reported as an ingredient of Praticilin in the following countries:
International Drug Name Search
Zyrona may be available in the countries listed below.
Cyproterone 17α-acetate (a derivative of Cyproterone) is reported as an ingredient of Zyrona in the following countries:
Ethinylestradiol is reported as an ingredient of Zyrona in the following countries:
International Drug Name Search
Pipamperon-neuraxpharm may be available in the countries listed below.
Pipamperone dihydrochloride (a derivative of Pipamperone) is reported as an ingredient of Pipamperon-neuraxpharm in the following countries:
International Drug Name Search
Plamet may be available in the countries listed below.
Bromopride is reported as an ingredient of Plamet in the following countries:
International Drug Name Search
Epufen may be available in the countries listed below.
Fentanyl is reported as an ingredient of Epufen in the following countries:
International Drug Name Search
USAN
0008031-14-9
C20-H35-Cl-O4-S
407
Antiseptic
Disinfectant
Hypochlorous acid complex of a mixture of the phenyl sulfonate derivatives of aliphatic hydrocarbons
International Drug Name Search
Glossary
| OS | Official Synonym |
| USAN | United States Adopted Name |
Pirorheum may be available in the countries listed below.
Piroxicam is reported as an ingredient of Pirorheum in the following countries:
International Drug Name Search
Piridoksina hidrohlorids may be available in the countries listed below.
Pyridoxine hydrochloride (a derivative of Pyridoxine) is reported as an ingredient of Piridoksina hidrohlorids in the following countries:
International Drug Name Search
Isee may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Chloramphenicol is reported as an ingredient of Isee in the following countries:
Retinol is reported as an ingredient of Isee in the following countries:
International Drug Name Search
Aclav may be available in the countries listed below.
Amoxicillin is reported as an ingredient of Aclav in the following countries:
Clavulanic Acid is reported as an ingredient of Aclav in the following countries:
International Drug Name Search
Distex may be available in the countries listed below.
Flurbiprofen is reported as an ingredient of Distex in the following countries:
International Drug Name Search
In the US, Prohist (chlophedianol/phenylephrine/triprolidine systemic) is a member of the drug class upper respiratory combinations and is used to treat Cough and Nasal Congestion.
US matches:
Promethazine hydrochloride (a derivative of Promethazine) is reported as an ingredient of Prohist in the following countries:
International Drug Name Search
Pirvinio pamoato may be available in the countries listed below.
Pirvinio pamoato (DCIT) is known as Pyrvinium in the US.
International Drug Name Search
Glossary
| DCIT | Denominazione Comune Italiana |
Noloten may be available in the countries listed below.
Amlodipine is reported as an ingredient of Noloten in the following countries:
Amlodipine besilate (a derivative of Amlodipine) is reported as an ingredient of Noloten in the following countries:
International Drug Name Search
Prednison Hexal may be available in the countries listed below.
Prednisone is reported as an ingredient of Prednison Hexal in the following countries:
International Drug Name Search
Vitakraft Color Reflex may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Dimpylate is reported as an ingredient of Vitakraft Color Reflex in the following countries:
International Drug Name Search
Propofol-ratiopharm may be available in the countries listed below.
Propofol is reported as an ingredient of Propofol-ratiopharm in the following countries:
International Drug Name Search
PVP-Jod-ratiopharm may be available in the countries listed below.
Povidone-Iodine is reported as an ingredient of PVP-Jod-ratiopharm in the following countries:
International Drug Name Search
PMS-Loxapine may be available in the countries listed below.
Loxapine succinate (a derivative of Loxapine) is reported as an ingredient of PMS-Loxapine in the following countries:
International Drug Name Search
Gen-Sumatriptan may be available in the countries listed below.
Sumatriptan succinate (a derivative of Sumatriptan) is reported as an ingredient of Gen-Sumatriptan in the following countries:
International Drug Name Search
Losartan-Kalium beta may be available in the countries listed below.
Losartan potassium salt (a derivative of Losartan) is reported as an ingredient of Losartan-Kalium beta in the following countries:
International Drug Name Search
Atenex may be available in the countries listed below.
Atenolol is reported as an ingredient of Atenex in the following countries:
International Drug Name Search
Amavita ASS + Vit. C may be available in the countries listed below.
Acetylsalicylic Acid is reported as an ingredient of Amavita ASS + Vit. C in the following countries:
Ascorbic Acid is reported as an ingredient of Amavita ASS + Vit. C in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Rec.INN
A03AB18
0004630-95-9
C22-H28-Br-N
386
Antispasmodic agent
Pyrrolidinium, 3-(diphenylmethylene)-1,1-diethyl-2-methyl-, bromide
International Drug Name Search
Glossary
| DCIT | Denominazione Comune Italiana |
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Pleyazen may be available in the countries listed below.
Secnidazole is reported as an ingredient of Pleyazen in the following countries:
International Drug Name Search
Haminclor may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Tosylchloramide Sodium is reported as an ingredient of Haminclor in the following countries:
International Drug Name Search
In the US, Alaway (ketotifen ophthalmic) is a member of the drug class ophthalmic antihistamines and decongestants and is used to treat Conjunctivitis, Allergic.
US matches:
Ketotifen is reported as an ingredient of Alaway in the following countries:
Ketotifen fumarate (a derivative of Ketotifen) is reported as an ingredient of Alaway in the following countries:
International Drug Name Search
Levoquinol may be available in the countries listed below.
Levofloxacin is reported as an ingredient of Levoquinol in the following countries:
International Drug Name Search
Benzalcort may be available in the countries listed below.
Benzyl Benzoate is reported as an ingredient of Benzalcort in the following countries:
International Drug Name Search
Eglymad may be available in the countries listed below.
Glimepiride is reported as an ingredient of Eglymad in the following countries:
International Drug Name Search
Ticlopidine Qualimed may be available in the countries listed below.
Ticlopidine hydrochloride (a derivative of Ticlopidine) is reported as an ingredient of Ticlopidine Qualimed in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Diclazuril is reported as an ingredient of Protazil in the following countries:
International Drug Name Search
Hjertemin may be available in the countries listed below.
Acetylsalicylic Acid is reported as an ingredient of Hjertemin in the following countries:
International Drug Name Search
Platfree may be available in the countries listed below.
Clopidogrel is reported as an ingredient of Platfree in the following countries:
International Drug Name Search
Generic Name: chlorpheniramine, hydrocodone, and phenylephrine (KLOR fe NEER a meen, HYE droe KOE done, FEN il EFF rin)
Brand Names: B-Tuss, Coughtuss, Cytuss HC, De-Chlor HC, DroTuss-CP, Ed-TLC, Ed-Tuss HC, Endal-HD Plus, H-C Tussive, Histussin-HC, Hydro-PC II, Hydro-PC II Plus, Hydron CP, Liquicough HC, Maxi-Tuss HCX, Mintuss MS, Neo HC, Poly-Tussin, Poly-Tussin HD, Relacon-HC, Relacon-HC NR, Relasin-HC, Rindal HD Plus, Rindal-HD, Triant-HC, Tusana-D, Z-Cof HC
Chlorpheniramine is an antihistamine that reduces the natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.
Hydrocodone is a narcotic cough medicine.
Phenylephrine is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).
The combination of chlorpheniramine, hydrocodone, and phenylephrine is used to treat runny or stuffy nose, sinus congestion, and cough caused by the common cold or flu.
Chlorpheniramine, hydrocodone, and phenylephrine may also be used for purposes not listed in this medication guide.
To make sure you can safely take this medication, tell your doctor if you have any of these other conditions:
asthma, COPD, sleep apnea, or other breathing disorder;
heart disease or high blood pressure;
diabetes;
a thyroid disorder;
curvature of the spine;
a history of head injury or brain tumor;
epilepsy or other seizure disorder;
low blood pressure;
glaucoma;
gallbladder disease;
Addison's disease or other adrenal gland disorders;
enlarged prostate, urination problems;
mental illness; or
a history of drug or alcohol addiction.
Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.
You may take this medication with or without food.
Measure liquid medicine with a special dose-measuring spoon or cup, not a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.
Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
Overdose symptoms may include extreme drowsiness, feeling restless or nervous, vomiting, stomach pain, warmth or tingly feeling, seizure (convulsions), pinpoint pupils, confusion, cold and clammy skin, weak pulse, shallow breathing, fainting, or breathing that stops.
severe dizziness, anxiety, restless feeling, or nervousness;
fast, pounding, or uneven heartbeats;
shallow breathing, slow heartbeat;
confusion, hallucinations, unusual thoughts or behavior;
feeling like you might pass out;
urinating less than usual or not at all;
easy bruising or bleeding, unusual weakness, fever, chills, body aches, flu symptoms;
dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, chest pain, shortness of breath, seizure); or
upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).
Less serious side effects may include:
nausea, vomiting, upset stomach, constipation;
dry mouth;
blurred vision;
dizziness, drowsiness;
problems with memory or concentration;
sleep problems (insomnia);
ringing in your ears;
warmth, tingling, or redness under your skin; or
skin rash or itching.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Tell your doctor about all other medications you use, especially:
blood pressure medication;
cimetidine (Tagamet);
rifampin (Rifadin, Rifater, Rifamate, Rimactane);
zidovudine (Retrovir, AZT);
an antidepressant;
a diuretic (water pill);
medication to treat irritable bowel syndrome;
bladder or urinary medications such as oxybutynin (Ditropan, Oxytrol) or tolterodine (Detrol);
aspirin or salicylates (such as Disalcid, Doan's Pills, Dolobid, Salflex, Tricosal, and others);
seizure medication such as phenytoin (Dilantin) or phenobarbital (Luminal, Solfoton);
a beta-blocker such as atenolol (Tenormin), carteolol (Cartrol), metoprolol (Lopressor, Toprol), nadolol (Corgard), propranolol (Inderal), sotalol (Betapace), timolol (Blocadren), and others; or
medicines to treat psychiatric disorders, such as chlorpromazine (Thorazine), haloperidol (Haldol), mesoridazine (Serentil), pimozide (Orap), or thioridazine (Mellaril).
This list is not complete and other drugs may interact with chlorpheniramine, hydrocodone, and phenylephrine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
See also: Relacon-HC NR side effects (in more detail)
B12 Depot-Rotexmedica may be available in the countries listed below.
Hydroxocobalamin acetate (a derivative of Hydroxocobalamin) is reported as an ingredient of B12 Depot-Rotexmedica in the following countries:
International Drug Name Search
Apo-Trazodone may be available in the countries listed below.
Trazodone hydrochloride (a derivative of Trazodone) is reported as an ingredient of Apo-Trazodone in the following countries:
International Drug Name Search
Aquinox may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Oxolinic Acid is reported as an ingredient of Aquinox in the following countries:
International Drug Name Search
Sunix may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Sulfadimethoxine sodium (a derivative of Sulfadimethoxine) is reported as an ingredient of Sunix in the following countries:
International Drug Name Search
Piroalgin may be available in the countries listed below.
Piroxicam is reported as an ingredient of Piroalgin in the following countries:
International Drug Name Search
Propofol Abbott may be available in the countries listed below.
Propofol is reported as an ingredient of Propofol Abbott in the following countries:
International Drug Name Search
0015421-15-5
C6-H7-K-O6
214
Mineral supplement
Potassium (2R)-2-[(1S)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2H-furan-3-olate (IUPAC)
Potassium L-ascorbate
International Drug Name Search
Glossary
| IUPAC | International Union of Pure and Applied Chemistry |
| IS | Inofficial Synonym |
Rec.INN
0056287-74-2
C16-H14-F-N3-O
283
Muscle relaxant, peripherally acting
4(3H)-Quinazolinone, 6-amino-2-(fluoromethyl)-3-(2-methylphenyl)-
International Drug Name Search
Glossary
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Lenamet Otc may be available in the countries listed below.
Cimetidine is reported as an ingredient of Lenamet Otc in the following countries:
International Drug Name Search
Vetio may be available in the countries listed below.
Mitomycin is reported as an ingredient of Vetio in the following countries:
International Drug Name Search
Pentamon may be available in the countries listed below.
Pentoxifylline is reported as an ingredient of Pentamon in the following countries:
International Drug Name Search
Cidilin may be available in the countries listed below.
Citicoline sodium salt (a derivative of Citicoline) is reported as an ingredient of Cidilin in the following countries:
International Drug Name Search
Phenyramidol may be available in the countries listed below.
Phenyramidol (BAN) is also known as Fenyramidol (Rec.INN)
International Drug Name Search
Glossary
| BAN | British Approved Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Class: Anti-inflammatory Agents
VA Class: GA900
Chemical Name: 3,3′-azobis[6-hydroxybenzoic acid disodium salt
Molecular Formula: C14H8N2Na2O6
CAS Number: 6054-98-4
Brands: Dipentum
Anti-inflammatory agent with GI tract activity; a 5-aminosalicylic acid derivative and a prodrug of mesalamine.1 2 4
Used to maintain clinical remission in patients who are intolerant of sulfasalazine.1 2 3 4 5 6
May be beneficial in the management of Crohn’s disease† involving the colon.4 40 41 42
Administer orally1 2 3 4 twice daily1 2 with food.1 4
Dosage of olsalazine sodium, which is commercially available as the disodium salt, is expressed in terms of olsalazine sodium.1
Daily dosage of 1g usually provides >0.9 g of mesalamine in the colon.1
500 mg twice daily.1 2 3 4
Known hypersensitivity to salicylates, olsalazine or its metabolites, or any ingredient in the formulation.1 43
Diarrhea (reported in about 17% of patients) 1 2 3 4 6 has required discontinuance in about 6% of patients.1 2 4
Diarrhea/loose stools, possibly dose-related,1 3 tend to occur within 1 week of initiating the drug or a dosage increase.2 4
Occasionally bloody2 and difficult to distinguish from underlying disease symptoms1 or may be distinguishable by its high water content and absence of blood.4 Possibly more severe and frequent in patients with extensive ulcerative colitis.2 4 5
Usually transient and dosage reduction or increased frequency of dosing of the drug and concomitant administration of food or an antidiarrhea agent (e.g., loperamide) may reduce severity.3 4
May resolve without dosage reduction3 and once it has resolved, may not recur.4
Exacerbation of preexisting symptoms of ulcerative colitis has been reported with other 5-aminosalicylic acid derivatives (e.g., mesalamine, sulfasalazine).1
Each g of olsalazine sodium, which contains the disodium salt, provides approximately 5.78 mEq (133 mg) of sodium.1 43
Category C.1
Distributed into milk in rats; not known whether distributed into human milk.1 Use caution.1
Safety and efficacy not established.1 43
Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.1
Use with caution in patients with renal impairment, since renal tubular damage has been reported in animals and rarely in postmarketing surveillance;1 perform urinalysis, monitor serum creatinine and BUN concentrations in such patients.1
Diarrhea/loose stools,1 2 3 4 6 abdominal pain or cramps,1 4 nausea,1 4 dyspepsia,1 heartburn,1 bloating,1 anorexia,1 vomiting,1 stomatitis,1 rectal bleeding,1 headache,1 2 4 fatigue,1 2 drowsiness,1 lethargy,1 depression,1 insomnia,1 vertigo,1 dizziness or lightheadedness,1 4 rash,1 2 4 pruritus,1 arthralgia or joint pain,1 4 upper respiratory infection.1
Drug | Interaction |
|---|---|
Warfarin | Potential interaction (increased prothrombin time).1 |
Olsalazine (prodrug) has limited systemic bioavailability; about 2.4% of an oral dose may be absorbed.1 4
Most (98–99%) of an oral dose reaches the colon intact1 2 3 4 resulting in very high local concentrations of the active metabolite mesalamine.1
Olsalazine: >99%;1 Mesalamine: 74%;1 N-acetyl-5-acetylsalicylic acid (a metabolite): 81%.1
Crosses placenta in animals.1
Distributed into milk in rats; not known whether distributed into human milk.1
Azo-linkage is cleaved in the colon by intestinal flora to form 2 molecules of mesalamine.1 2 3 4
Mesalamine is rapidly acetylated in colonic epithelium and liver to N-acetyl-5-acetylsalicylic acid.1 4 6
0.1% of olsalazine is metabolized in the liver to olsalazine-O-sulfate.1 4
Mesalamine is excreted principally in feces as N-acetyl-5-acetylsalicylic acid,1 4 6 and to a lesser extent in urine (about 20%) mostly as N-acetyl-5-acetylsalicylic acid;7 9 25 <1% of olsalazine excreted in urine unchanged.1
Olsalazine: approximately 0.9 hours.1 Olsalazine-O-sulfate: 7 days.1
25°C (may be exposed to 15–30°C).1
Prodrug with little or no anti-inflammatory activity until cleaved to form mesalamine (active moiety).1 2 3 4 6
Exerts local (not systemic) anti-inflammatory effects in the GI tract.1 2 3 4 7 8 9 10 11 12 13 14 15 17 18 19 21 23 24 26 27 28 29 30 31 32 35 33 34 36 38
May reduce inflammation in the colon by inhibiting cyclooxygenase and lipoxygenase, which catalyze the formation of prostaglandin precursors (endoperoxides) and of leukotrienes and hydroxyeicosatetraenoic acids, respectively, from arachidonic acid and/or its metabolites.1 4 7 8 9 11 12 13 14 15 16 18 19 20 21 23 32 35 38 39
Importance of taking with food.1
Importance of taking in equally divided doses.1
Importance of informing clinicians if diarrhea occurs.1
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.1
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1
Importance of advising patients of other important precautionary information. (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Oral | Capsules | 250 mg | Dipentum | Celltech |
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Dipentum 250MG Capsules (ALAVEN PHARMACEUTICAL LLC): 100/$229.96 or 300/$656.01
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions September 2005. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
† Use is not currently included in the labeling approved by the US Food and Drug Administration.
1. Celltech. Dipentum (olsalazine) capsules prescribing information. Rochester, NY; 2002 Sep.
2. Sandberg-Gertzen H, Jarnerot G, Kraaz W. Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse prevention properties. Gastroenterol. 1986:90:1024-30. (IDIS 214428)
3. Ireland A, Mason CH, Jewell DP. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut. 1988; 29:835-7. [IDIS 243681] [PubMed 2898422]
4. Wadworth AN, Fitton A. Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in inflammatory bowel disease. Drugs. 19911; 41:647-64.
5. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. Am J Gastroenterol. 1997; 92:204-11. [IDIS 382198] [PubMed 9040192]
6. Sandborn WJ. Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. Am J Gastroenterol. 2002; 97:2939-41. (IDIS 492059)
7. Salix Pharmaceuticals. Colazal (balsalazide disodium) capsules prescribing information. Raleigh, NC; 2000 Jul.
8. Prakash A, Spencer CM. Balsalazide. Drugs. 1998; 56:83-9. [PubMed 9664201]
9. Novartis, East Hanover, NJ: Personal communication.
10. Anon. Oral balsalazide (Colazal) for ulcerative colitis. Med Lett Drugs Ther. 2001; 43:62-3. [PubMed 11468602]
11. Reid-Rowell. Rowasa (mesalamine) prescribing information. Marietta, GA; (5EKI0, 1990).
12. Reid-Rowell. Rowasa (mesalamine): a product profile. Marietta, GA; 1988 Mar.
13. Bondesen S, Rasmussen SN, Rask-Madsen J et al. 5-Aminosalicylic acid in the treatment of inflammatory bowel disease. Acta Med Scand. 1987; 221:227-42. [IDIS 232774] [PubMed 3296672]
14. Weintraub M, Evans P. 5-Aminosalicylic acid: an old, ‘new’ treatment for inflammatory bowel disease. Hosp Formul. 1987; 22:528-33.
15. Peppercorn MA. Sulfasalazine and related new drugs. J Clin Pharmacol. 1987; 260-5. (IDIS 228622)
16. Reid-Rowell. Rowasa (mesalamine) product information form for the American Hospital Formulary Service. Marietta, GA; 1988 Apr. 17.
17. Anon. Mesalamine for ulcerative colitis. Med Lett Drugs Ther. 1988; 30:53-6. [PubMed 3283508]
18. Ligumsky M, Karmeli F, Sharon P et al. Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology. 1981; 81:444-9. [IDIS 139848] [PubMed 6114012]
19. Sharon P, Ligumsky M, Rachmilewitz D et al. Role of prostaglandins in ulcerative colitis. Gastroenterology. 1978; 75:638-40. [PubMed 30669]
20. Lauritsen K, Laursen LS, Bukhave K et al. Effects of topical 5- aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology. 1986; 91:837-44. [IDIS 221448] [PubMed 3017804]
21. Donowitz M. Arachidonic acid metabolites and their role in inflammatory bowel disease: update requiring addition of a pathway. Gastroenterology. 1985; 88:580-7. [IDIS 196055] [PubMed 2856909]
22. Sharon P, Stenson WF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology. 1984; 86:453-60. [PubMed 6319219]
23. Kirsner JB, Shorter RG. Recent developments in ‘nonspecific’ inflammatory bowel disease: first of two parts. N Engl J Med. 1982; 306:775-85. [IDIS 146719] [PubMed 7038488]
24. Campieri M, Lanfranchi GA, Boschi S et al. Topical administration of 5- aminosalicylic acid enemas in patients with ulcerative colitis: studies on rectal absorption and excretion. Gut. 1985; 26:400-5. [IDIS 203829] [PubMed 3979912]
25. Dew MJ, Ebden P, Kidwai NS et al. Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-amino salicylic acid in normal subjects and patients with colitis. Br J Clin Pharmacol. 1984; 17:474-6. [IDIS 184171] [PubMed 6144318]
26. Klotz U. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet. 1985; 10:285-302. [IDIS 203379] [PubMed 2864155]
27. Campieri M, Lanfranchi GA, Brignola C et al. 5-ASA blood levels in topical treatment of ulcerative colitis: preliminary observations. Scand J Gastroenterol. 1982; 17:(Suppl)500.
28. Fischer C, Maier K, Stumpf E et al. al. Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man. Eur J Clin Pharmacol. 1983; 25:511-5. [IDIS 179570] [PubMed 6140167]
29. Dew MJ, Cardwell M, Kidwai NS. et. al. 5-Aminosalicylic acid in serum and urine after administration by enema to patients with colitis. J Pharm Pharmacol. 1983; 35:323-4. [IDIS 170825] [PubMed 6134804]
30. Pieniaszek HJ Jr, Bates TR. Capacity-limited gut wall metabolism of 5- aminosalicylic acid, a therapeutically active metabolite of sulfasalazine, in rats. J Pharm Sci. 1979; 68:1323-5. [PubMed 41931]
31. Klotz U, Maier K, Fischer C et al. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn’s disease. N Engl J Med. 1980; 303:1499-1502. [IDIS 125198] [PubMed 6107853]
32. Cooper BT. Sulphasalazine in inflammatory bowel disease: recent advances. N Z Med J. 1986; 99:757-9. [IDIS 231591] [PubMed 2877428]
33. Campieri M, Lanfranchi GA, Brignola C et al. 5-Aminosalicylic acid for the treatment of inflammatory bowel diseases. Gastroenterology. 1985; 89:701-2. [IDIS 203789] [PubMed 4018510]
34. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderatel active ulcerative colitis. N Engl J Med. 1987; 317:1625-9. [IDIS 236262] [PubMed 3317057]
35. Peskar BM, Dreyling KW, May B, et. al. Possible mode of action of 5-aminosalicylic acid. Dig Dis Sci. 1987; 32(Suppl)51-6S. (PubMed 2891468)
36. McPhee MS, Swan JT, Biddle WL et al. al. Proctocolitis unresponsive to conventional therapy. Dig Dis Sci. 1987; 32:(Suppl)76-81S. [IDIS 317556] [PubMed 3319462]
37. Kirsner JB. Observations on the medical treatment of inflammatory bowel disease. JAMA. 1980; 243:557-64. [IDIS 107851] [PubMed 6101350]
38. Allgayer H, Stenson WF. A comparison of effects of sulfasalazine and its metabolites on the metabolism of endogenous vs. exogenous arachidonic acid. Immunopharmacology. 1988; 15:39-46. [PubMed 2896181]
39. Hoult JRS, Page H. 5-Aminosalicylic acid, a co-factor for colonic prostacyclin synthesis? Lancet. 1981; 2:255. Letter.
40. Blomqvist P, Feltelius N, Lofberg R et al. A 10-year survey of inflammatory bowel diseases-drug therapy, costs and adverse reactions. Aliment Pharmacol Ther. 2001; 15:475-81. [PubMed 11284775]
41. Podolsky DK. Inflammatory Bowel Disease. N Engl J Med. 2002; 347:417-29. [IDIS 484721] [PubMed 12167685]
42. Hanauer SB. Inflammatory bowel disease. N Engl J Med. 1996; 334:841-8 [IDIS 361805] [PubMed 8596552]
43. Celltech, Rochester, NY: Personal communication.
